Hypertrophic Cardiomyopathy in Noonan Syndrome Treated by MEK-Inhibition

J Am Coll Cardiol. 2019 May 7;73(17):2237-2239. doi: 10.1016/j.jacc.2019.01.066.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural

MeSH terms

  • Cardiomyopathy, Hypertrophic / complications
  • Cardiomyopathy, Hypertrophic / congenital
  • Cardiomyopathy, Hypertrophic / drug therapy*
  • Female
  • Gestational Age
  • Humans
  • Infant, Newborn
  • MAP Kinase Kinase Kinase 1 / genetics*
  • Mutation / genetics
  • Noonan Syndrome / complications
  • Noonan Syndrome / diagnosis
  • Noonan Syndrome / genetics*
  • Pregnancy
  • Prognosis
  • Protein Kinase Inhibitors / therapeutic use
  • Pyridones / therapeutic use*
  • Pyrimidinones / therapeutic use*
  • Rare Diseases
  • Risk Assessment
  • Sampling Studies
  • Treatment Outcome
  • Ultrasonography, Prenatal / methods

Substances

  • Protein Kinase Inhibitors
  • Pyridones
  • Pyrimidinones
  • trametinib
  • MAP Kinase Kinase Kinase 1